Drug Trial Radar · NCT06367465
Feasibility and Acceptability of HCV Treatment in Pregnancy
Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Feb 1, 2024
Primary completion
Dec 28, 2026
Study completion Dec 28, 2026
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 16, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
Summary
As written by the sponsor on the registry.
Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use Participant Duration: Approximately 1 year. Aims: Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs. Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.
Conditions
- Hepatitis C
- Pregnancy Complications
Interventions
Glecaprevir-pibrentasvirDrug
Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Medication adherence and treatment completion rates.Time frame: 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Barnes Jewish Hospital
St Louis, Missouri · Recruiting
Washington Univeristy
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.